^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD3 agonist

    Related drugs:
    23h
    Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1/2, N=189, Recruiting, Excyte Biopharma Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    A Phase I Study of YK012 in Primary Membranous Nephropathy (clinicaltrials.gov)
    P1, N=66, Not yet recruiting, Excyte Biopharma Ltd | Initiation date: Feb 2026 --> Oct 2026
    Trial initiation date
    1d
    Shared PRAME epitopes are T-cell targets in NUT carcinoma. (PubMed, J Immunother Cancer)
    PRAME is highly and frequently expressed in NUT carcinoma, and the most common oncoprotein causing NUT carcinoma, BRD4::NUTM1, contributes to these high PRAME levels. PRAME epitopes presented by HLA class I are a previously unrecognized therapeutic vulnerability for NUT carcinoma that warrants clinical trials testing PRAME-targeted immunotherapies in this neglected patient population.
    Journal • IO biomarker
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • NSD3 (Nuclear Receptor Binding SET Domain Protein 3) • PRAME (Preferentially Expressed Antigen In Melanoma) • BRD4 (Bromodomain Containing 4) • NUTM1 (NUT Midline Carcinoma Family Member 1) • BRD3 (Bromodomain Containing 3)
    |
    brenetafusp (IMC-F106C)
    1d
    GO39775: Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) (clinicaltrials.gov)
    P1, N=355, Completed, Genentech, Inc. | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Jan 2026 | Trial primary completion date: Apr 2026 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Actemra IV (tocilizumab) • cevostamab (RG6160)
    1d
    Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformation. (PubMed, Blood Adv)
    Given the favorable toxicity profile of mosunetuzumab, and rapid and durable complete responses observed in this cohort, further investigation of mosunetuzumab for the treatment of RT, as monotherapy and in combination with other novel agents or chemotherapy, is warranted. NCT02500407.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Lunsumio (mosunetuzumab-axgb)
    2d
    A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) (clinicaltrials.gov)
    P1/2, N=242, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Aug 2029 --> Feb 2030
    Trial completion date
    |
    Imfinzi (durvalumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)
    2d
    GLO-PACT: Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, American University of Beirut Medical Center
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    Columvi (glofitamab-gxbm)
    2d
    MERLIN: Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients (clinicaltrials.gov)
    P2, N=37, Recruiting, Fundación GECP | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Imdelltra (tarlatamab-dlle)
    2d
    RAGNAR: Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab (clinicaltrials.gov)
    P2, N=87, Recruiting, Grupo Espanol de Tumores Neuroendocrinos | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Dec 2025
    Enrollment open • Trial initiation date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    5-fluorouracil • irinotecan • leucovorin calcium • Imdelltra (tarlatamab-dlle)
    2d
    Celestimo: A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma (clinicaltrials.gov)
    P3, N=478, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Jan 2026 --> May 2026
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • lenalidomide • Lunsumio (mosunetuzumab-axgb)
    3d
    GLOBRYTE: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P3, N=182, Recruiting, Hoffmann-La Roche | Trial completion date: Sep 2027 --> Mar 2028 | Trial primary completion date: Feb 2027 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    Rituxan (rituximab) • lenalidomide • Gazyva (obinutuzumab) • bendamustine • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)